W

bioLLM/wiki

LLM-Synthesized Biotech Database

Live

placebo capsules

placebo capsules

Overview

Placebo capsules are pharmacologically inert oral dosage forms — typically filled with inactive substances such as medium-chain triglyceride (MCT) oil, starch, or cellulose — designed to be visually and physically indistinguishable from active investigational treatments. Their primary role in biomedical research is as a comparator in controlled clinical trials, where they enable rigorous evaluation of a therapeutic agent's efficacy by isolating the pharmacological effect from expectation-driven responses, participant behavior, and natural disease progression. The use of placebo capsules is foundational to the randomized, double-blind, placebo-controlled trial (RCT), widely regarded as the gold standard of clinical evidence generation.

Beyond their methodological function, placebo capsules hold genuine scientific interest in their own right. The psychological and neurobiological responses elicited by placebo administration — including placebo analgesia, nocebo-induced symptom worsening, and expectation-driven cognitive effects — represent active areas of investigation. These phenomena, mediated through endogenous opioid pathways, top-down cortical modulation, and conditioned learning, underscore that the act of receiving an inert capsule is not a neutral event but one capable of producing measurable physiological and cognitive changes. Understanding and controlling for these effects is central to the integrity of modern clinical pharmacology.

Focus of Latest Publications

Recent publications involving placebo capsules span a range of randomized and blinded study designs, most often as the comparator for active therapies. In a phase 3 trial in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease, placebo capsules were used alongside once-weekly subcutaneous survodutide; the active treatment was statistically and clinically superior to placebo for reducing MRI-PDFF-assessed liver fat content and body weight over 48 weeks. Placebo was also used in a multicentre randomized trial protocol in critical illness-related corticosteroid insufficiency, where hydrocortisone plus fludrocortisone is being tested against placebo to improve organ dysfunction-free survival in critically ill patients.

Placebo capsules also appear in studies of acute and symptomatic conditions. A multicenter randomized double-blind placebo-controlled trial evaluated intravenous fosphenytoin for acute trigeminal neuralgia exacerbations, with the study designed to test whether the active treatment reduces pain compared with placebo. In a protocol for surgery in wrist osteoarthritis, placebo or sham surgery is the comparator framework for assessing the benefits and harms of partial wrist fusion and other surgical options in adults with non-inflammatory wrist osteoarthritis.

Other recent publications used placebo in mechanistic or subgroup analyses of larger randomized datasets. In the REVISE trial protocol and statistical analysis plan, pantoprazole is compared with placebo in invasively ventilated critically ill adults with septic shock to evaluate stress ulcer prophylaxis outcomes, including clinically important upper gastrointestinal bleeding and mortality. In a phase 2b spinal cord injury study, NG101 was compared with placebo, and MRI biomarkers suggested faster lesion volume reduction and slower decline in spinal cord macro- and microstructural measures with NG101. A Bayesian analysis of FINEARTS-HF also examined finerenone versus placebo in heart failure with mildly reduced or preserved ejection fraction to estimate the probability of different magnitudes of benefit and safety.

Beyond direct therapeutic comparisons, placebo-related methodology remains relevant in broader evidence synthesis. One publication on seasonal vaccines highlighted that definitions of placebo or unvaccinated controls can affect network connectivity and feasibility assessments in network meta-analysis, underscoring the importance of how placebo-controlled studies are incorporated into comparative effectiveness research. Another study in older adults examined placebo and nocebo suggestion in an online cognitive task, finding that negative expectations impaired performance while positive placebo suggestions mainly influenced subjective beliefs rather than objective cognitive outcomes.

Key Publications

  • NEWJun Considerations for assessing the feasibility of network meta-analysis of seasonal vaccines. (Journal of comparative effectiveness research, 2026, PMID 42370650): "the impact of seasonality, strain evolution and definitions of placebo/unvaccinated controls on network connectivity;"
  • NEWJun Surgery for wrist osteoarthritis. (The Cochrane database of systematic reviews, 2026, PMID 42318886): "The primary objective is to assess the benefits and harms of partial wrist fusion compared with placebo or sham surgery in adults with non-inflammatory osteoarthritis of the wrist."
  • NEWJun HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency (HORNbILL): study protocol for a multicentre randomised placebo-controlled trial. (BMJ open, 2026, PMID 42309657): "This trial aims to determine whether, through biomarker enrichment using CIRCI criteria, hydrocortisone and fludrocortisone, compared with placebo, improve organ dysfunction-free survival in critically ill patients."
  • NEWJun Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. (Nature medicine, 2026, PMID 42252333): "In adults with obesity and at-risk MASLD, survodutide treatment was statistically and clinically superior to placebo for reductions in MRI-PDFF-assessed LFC and body weight."
  • Jul Pantoprazole Use in Invasively Ventilated Patients With Septic Shock: A Protocol and Statistical Analysis Plan. (Acta anaesthesiologica Scandinavica, 2026, PMID 42186360): "This protocol describes the rationale, methods, and statistical analysis plan for a post hoc subgroup analysis evaluating pantoprazole versus placebo in invasively ventilated critically ill adults with septic shock enrolled in the REVISE trial (NCT03374800)."
  • May Beyond expectations: nocebo suggestion affects cognitive performance in older adults. (Psychological research, 2026, PMID 42138727): "Understanding these effects is relevant for designing interventions that leverage positive expectations to enhance cognitive outcomes while mitigating negative expectations, especially for older adults facing age-related cognitive decline."
  • May Anti-Nogo-A NG101 treatment induces changes in spinal cord micro- and macrostructure following spinal cord injury. (Nature communications, 2026, PMID 42120375): "Compared to placebo, NG101-treated participants exhibited faster lesion volume reduction and a slower decline of CSA and MTsat in the corticospinal tracts and dorsal columns."
  • May IV Fosphenytoin for Acute Trigeminal Neuralgia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. (Neurology, 2026, PMID 42096672): "We hypothesized that, compared with placebo, IFT would reduce acute TN pain."
  • May A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF. (European heart journal. Cardiovascular pharmacotherapy, 2026, PMID 41697954): "The aim of this study was to estimate the probability of different magnitudes of treatment benefit with finerenone vs. placebo using Bayesian analysis of FINEARTS-HF."
Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.